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Abstract
Background: Fatigue is one of the most commonly reported and debilitating symptoms of multiple sclerosis (MS); 
approximately two-thirds of people with MS consider it to be one of their three most troubling symptoms. It may limit 
or prevent participation in everyday activities, work, leisure, and social pursuits, reduce psychological well-being and is 
one of the key precipitants of early retirement. Energy effectiveness approaches have been shown to be effective in 
reducing MS-fatigue, increasing self-efficacy and improving quality of life. Cognitive behavioural approaches have 
been found to be effective for managing fatigue in other conditions, such as chronic fatigue syndrome, and more 
recently, in MS. The aim of this pragmatic trial is to evaluate the clinical and cost-effectiveness of a recently developed 
group-based fatigue management intervention (that blends cognitive behavioural and energy effectiveness 
approaches) compared with current local practice.
Methods/Design: This is a multi-centre parallel arm block-randomised controlled trial (RCT) of a six session group-
based fatigue management intervention, delivered by health professionals, compared with current local practice. 180 
consenting adults with a confirmed diagnosis of MS and significant fatigue levels, recruited via secondary/primary care 
or newsletters/websites, will be randomised to receive the fatigue management intervention or current local practice. 
An economic evaluation will be undertaken alongside the trial. Primary outcomes are fatigue severity, self-efficacy and 
disease-specific quality of life. Secondary outcomes include fatigue impact, general quality of life, mood, activity 
patterns, and cost-effectiveness. Outcomes in those receiving the fatigue management intervention will be measured 
1 week prior to, and 1, 4, and 12 months after the intervention (and at equivalent times in those receiving current local 
practice). A qualitative component will examine what aspects of the fatigue management intervention participants 
found helpful/unhelpful and barriers to change.
Discussion: This trial is the fourth stage of a research programme that has followed the Medical Research Council 
guidance for developing and evaluating complex interventions. What makes the intervention unique is that it blends 
cognitive behavioural and energy effectiveness approaches. A potential strength of the intervention is that it could be 
integrated into existing service delivery models as it has been designed to be delivered by staff already working with 
people with MS. Service users will be involved throughout this research.
Trial registration: Current Controlled Trials ISRCTN76517470
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Background
Multiple sclerosis (MS) is a chronic, unpredictable, incur-
able, demyelinating disease of the central nervous system
affecting approximately 2.5 million people [1-3]. It is
more common in women and onset peaks between 20
and 40 years. The causes and early development of the
disease are not fully understood but probably involve
immune, genetic, and environmental factors [2,3].
Fatigue is one of the most commonly reported and dis-
abling symptoms of MS, often occurring daily [4] and
with a variable course [5,6]. Up to 86% of individuals with
MS experience fatigue at any one time; 65% consider it to
be one of their three most troubling symptoms [4].
Fatigue has been defined as a 'subjective lack of physical
and/or mental energy that is perceived by the individual
or caregiver to interfere with usual or desired activities',
p. 2 [7]. The pathophysiology of fatigue is unclear [8] but
likely to be multi-factorial [9,10]. Findings on the rela-
tionships between fatigue and other clinical variables
(such as age, gender, disease duration, and clinical activ-
ity) have been equivocal [11].
Researchers have distinguished between primary and
secondary fatigue [12]. 'Primary' fatigue relates to aspects
of fatigue deemed to be directly related to the disease
process such as lassitude or asthenia (an overwhelming
sense of tiredness not directly related to participation in
activity or exercise), 'short-circuiting' fatigue (when mus-
cular performance deteriorates during sustained activity
but recovers after a short rest break) and heat sensitive
fatigue (where fatigue is triggered or worsened by heat).
'Secondary' fatigue refers to fatigue that is not unique to
M S  a n d  i s  r e l a t e d  t o  f a c t o r s  c o m m o n  t o  a  r a n g e  o f
chronic and disabling conditions (e.g. sleep disturbance,
medication side effects, infection, physical exertion,
depression, anxiety, stressful life events, characteristics of
the local environment - such as lighting and temperature
within a work setting). The relationship between these
dimensions is complex; various symptoms of MS may act
as predisposing factors for secondary fatigue.
Fatigue may limit or prevent participation in everyday
activities, work, leisure and social pursuits, restrict role
fulfilment and reduce psychological well-being [12,13]
and is one of the key precipitants of early retirement
[14,15]. Its 'invisible' nature may lead to difficulties in per-
sonal and work relationships [16,17].
Fatigue is highly related to an individual's sense of con-
trol over MS and psychological well-being [13,18,19].
Sense of control has been found to predict lower levels of
fatigue [20], suggesting that increasing self-efficacy
related to fatigue could improve quality of life.
Pharmacological and non-pharmacological treatments
are available for MS-related fatigue, but evidence on
effectiveness is mostly inconclusive or non-existent
[4,21,22]. Non-pharmacological studies exploring the
effectiveness of energy conservation programmes for
MS-fatigue have tended to be small and uncontrolled [23-
27]. Two fatigue management initiatives have been devel-
oped in the UK [28,29]. Only the former has been evalu-
ated and numbers were small. In the USA, a randomised
controlled trial (RCT) [30] of an energy conservation
course [31] found evidence for its effectiveness in reduc-
ing fatigue impact, increasing self-efficacy and aspects of
quality of life; benefits were maintained at 1 year [32].
Results from a German adaptation were also promising
[33]. A RCT that evaluated a multi-disciplinary fatigue
management programme [34] demonstrated no reduc-
tion in fatigue impact compared with a placebo interven-
tion.
Although the important relationships between physical
and psychological aspects of MS-fatigue are recognised
[35], high quality RCTs of psychological interventions are
rare [36]. In Chronic Fatigue Syndrome (CFS) individual
Cognitive Behavioural Therapy (CBT) is effective in
treating fatigue [37,38]. A systematic review [39] of psy-
chological interventions for MS identified just one RCT
that used a cognitive behavioural approach to manage
MS-fatigue [40]. The intervention consisted of individual
CBT conducted by a clinical psychologist and was shown
to be effective in reducing fatigue. However, in the UK
National Health Service (NHS), and elsewhere, psycholo-
gists working with people with MS are scarce, thus this
approach may prove impractical [39].
A number of pilot studies have used group-based cog-
nitive behavioural approaches, either in the context of
coping with MS [41-43], or specifically with MS-fatigue
[44]. Group-based approaches are potentially more cost
effective than one-to-one and offer opportunities for peer
support. Recently, we have developed a group-based
manualised fatigue intervention for the management of
MS-fatigue that incorporates energy effectiveness and
cognitive behavioural approaches [45]. This intervention
involves health professionals routinely involved in the
management of MS, supported by clinical psychologists,
and is thus compatible with a wide range of existing
health service structures (such as the UK National Health
Service (NHS)). Pilot work has been encouraging and this
trial is a formal evaluation of the effectiveness of the
intervention [45].
Aims
Patient population: Adults with multiple sclerosis experi-
encing significant fatigue that is impacting on daily life.
Primary aim
1. To test whether those allocated to the group-based
cognitive behavioural fatigue management intervention
differ (in terms of fatigue severity, self-efficacy, and MS-
specific quality of life) from those allocated to current
local practice.Thomas et al. BMC Neurology 2010, 10:43
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Secondary aims
2. To test whether those allocated to a group-based cogni-
tive behavioural fatigue management intervention differ
(in terms of fatigue impact, mood, general quality of life,
and activity patterns) from those allocated to current
local practice.
3. To assess how the group-based cognitive behavioural
intervention and current local practice differ in terms of
cost-effectiveness.
4. For those who attend the group-based programme,
to gather feedback about experiences of attending the
programme, any changes made and barriers to change
encountered, and helpful or unhelpful aspects.
Methods/Design
Trial design
This is a parallel arm randomised controlled trial com-
paring a group-based cognitive behavioural approach to
managing fatigue (Fatigue Management Programme
(FMP)) with current local practice. The trial design is
summarised in Figure 1.
This RCT is the fourth stage of a research programme
that has followed the Medical Research Council (MRC)
guidance for developing and evaluating complex inter-
ventions [46]. The pilot work has been published [45].
Participants will be randomised to receive the fatigue
management intervention or current local practice. A
placebo arm to the trial was considered but rejected
because (a) the fatigue management programme is a
"complex intervention" (incorporating group, educa-
tional, cognitive, behavioural, and energy effectiveness
components and the attendance of supportive others)
making it difficult to know which "active ingredients" to
control for in the placebo; (b) of the difficulties inherent
in designing a placebo intervention that is credible to par-
ticipants and facilitators, and that maintains participant
masking, and (c) in clinical practice, the costs of deliver-
ing the fatigue management programme and the sham
intervention would be equivalent.
The pilot research (multi-centre pilot) undertaken
identified practical difficulties involved in running a three
centre randomised trial. The multi-centre approach for
the randomised trial will help to ensure sufficient num-
bers of participants are recruited and that results are gen-
eralisable outside Poole, where the intervention was
developed.
Setting
The trial is taking place in three centres (Poole, Bristol,
Southampton/Portsmouth) and each centre has a team of
trained facilitators to deliver the fatigue management
programme.
Ethical, governance and management considerations
This trial has been reviewed and given a favourable opin-
ion by the North Somerset and South Bristol Multi-Cen-
tre Research Ethics Committee (ref: 08/H0106/2). Poole
Hospital NHS Foundation Trust is acting as sponsor. The
study is funded by a project grant awarded by the Multi-
ple Sclerosis Society of Great Britain and Northern Ire-
land. The study is included in the National Institute of
Health Research Clinical Research Network (NIHR CRN)
portfolio (ID 4843).
As the trial involves people with MS and fatigue, careful
consideration will be given to the location of the inter-
vention (e.g. public transportation, car parking, walking
distances), and the comfort of the participants (room
temperature, refreshment breaks, cushioned chairs etc.).
Because participants will have fatigue, the length of ses-
sions in the fatigue management programme has been
kept reasonably short, and the number and length of out-
come measures have been kept to a minimum. Two facili-
t a t o r s  w i l l  r u n  e a c h  s e s s i o n .  I f  s o m e o n e  b e c o m e s
emotionally upset or unwell during a session, one of the
facilitators can take that person aside, and provide infor-
mation regarding help and support available from local
MS services (such as a MS Specialist Nurse), the MS
Society and MS Trust, and primary care (General Prac-
tice, counselling services etc.).
A  t r i a l  s t e e r i n g  g r o u p  w i l l  m e e t  a t  r e g u l a r  i n t e r v a l s
throughout the trial.
Service user support
There has been service user involvement in all stages of
the research so far, including the development of this pro-
tocol. Service users will be represented on the trial steer-
ing group.
Data protection
All information that is collected will be kept strictly con-
fidential and any information that leaves Poole Hospital
will not contain any personal details. Questionnaires will
be allocated a participant identification number; they will
not contain any names or identifying details. Only the
authorised members of the research team will have access
to the trial data.
Participants
Sample size
Sample size consideration is mostly based upon fatigue as
the primary outcome measure; this is the outcome mea-
sure used most frequently in other trials that include peo-
ple with fatigue. As a variety of fatigue measures have
been used in other trials, we have used standardised
effect sizes to enable comparisons between them. Stan-
dardised effect sizes of 0.2 are commonly considered
small, 0.5 considered medium, and 0.8 considered large
[47]. In this trial, we will aim to detect a medium effect
size. The Cochrane systematic review of cognitive behav-
ioural therapy in people with CFS [38] identified two
good quality studies, and in these the standardised effect
sizes for fatigue were 0.7 and 1.0. The Cochrane System-Thomas et al. BMC Neurology 2010, 10:43
http://www.biomedcentral.com/1471-2377/10/43
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Figure 1 Flowchart of trial design.
180 eligible,
consenting 
participants
Randomisation
(stratified by centre)
Baseline Assessment - 5 weeks post-randomisation 
[Equivalent to 1 week pre-intervention in FMP arm]
Follow-up assessment (2) - 7 months post-randomisation
[Equivalent to 4 months post-intervention in FMP arm] 
Follow-up assessment (1) - 4 months post-randomisation
[Equivalent to 1 month post-intervention in FMP arm]
Fatigue
Management
Programme
Current
Local 
Practice
Follow-up assessment (3) - 15 months post-randomisation
[Equivalent to 12 months post-intervention in FMP arm] Thomas et al. BMC Neurology 2010, 10:43
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atic Review of Amantadine for fatigue in MS found effect
sizes of between 0.3 and 1.4 for the three studies that
measured fatigue on a continuous scale [21]. Thus, our
choice of an effect size seems reasonable in the context of
(a) how well cognitive behavioural approaches work in
another chronic disease where fatigue is a major symp-
tom, and (b) how well another treatment for fatigue
works in MS. For 85% power, the sample size requirement
(using a two-tailed 5% significance level) is 73 people per
arm of the trial; 146 in total. Inevitably, there will be some
participants who withdraw from the trial during its
course, or more generally, do not complete outcome mea-
sures. To allow for this, we will aim to enrol 180 partici-
pants; 90 in each arm of the trial. Thus, if 20% of
participants do not provide data on the primary outcome
measures, the study would maintain statistical power.
This figure of 20% will be reviewed during the study and
sample size adjusted up or down accordingly.
Eligibility criteria
Inclusion criteria
1. Providing written informed consent.
2. Over the age of 18.
3. Clinical diagnosis of relapsing-remitting or pro-
gressive multiple sclerosis (Poser/McDonald criteria 
[48-50].
4. Score on the Fatigue Severity Scale (FSS) [51] 
greater than 4. The FSS is a uni-dimensional self-
report measure consisting of 9 items that ask about 
severity of fatigue related to daily activities (such as 
physical functioning, exercise, work, family, and 
social life). Responses are made on a 7-point Likert-
type scale.
5. Ambulatory (score on the Adapted Patient Deter-
mined Disease Steps (APDDS) Scale [52] < 8). This 
self-administered instrument is based on the Patient-
Determined Disease Steps (PDDS) scale and the tele-
phone Expanded Disability Status Scale (EDSS). The 
programme content will be most relevant for those 
who are ambulatory. Individuals who are non-ambu-
latory will continue to receive standard care.
6. Able to attend the intervention sessions.
7. English speaking.
Exclusion criteria
1. Attended a specific fatigue management programme
within the last year.
2. Received a substantive, specific, fatigue intervention
from an Occupational Therapist (OT) or other health
professional, consisting of more than general advice,
within the previous 3 months (such as the guidance pro-
duced by the National Association of Neurological Occu-
pational Therapists (NANOT) [53] (now known as the
College of Occupational Therapists Specialist Section -
Neurological Practice) [29].
3. Already involved in another research study.
4. Individuals who have cognitive deficits such that they
would not be able to engage in the group format or bene-
fit from the programme. If individuals have substantial
cognitive deficits much of the content of the fatigue man-
agement programme would not be appropriate. This will
be based on the judgement of health professionals/local
investigators.
5. Individuals who have had a relapse within the previ-
ous three months. This would be a potential confound
since a change in fatigue could be the result of treatment
or improvement after a recent relapse.
6. Individuals who have been on a disease-modifying
drug (such as Beta-Interferon, Glatiramer Acetate) or an
anti-depressant for fewer than 3 months. One of the pos-
sible initial side effects of these drugs is fatigue and thus
this could be a confounder.
7. Individuals who are known to be currently under the
care of a psychiatrist or under the care of addiction ser-
vices will be excluded. Ongoing psychiatric disorders or
addiction problems would compromise the potential to
benefit from the programme.
Individuals excluded from the research project will
continue to be seen as per usual care.
Source of participants
The recruitment target for each of the three centres will
be 60 people, of whom 30 will receive the group-based
intervention. In each centre this will require running
three successive iterations of the programme, recruiting
i n  b l oc ks  o f  a r o u n d  2 0 .  T h e  f a t i g u e  m a n a g e m e n t  p r o -
gramme has been designed for groups of between 6-12
participants.
Participants will be recruited using a variety of meth-
ods; via MS Services/Neurology Departments, MS Soci-
ety newsletters and website, other relevant newsletters,
MS Research database, MS support groups, General
Practitioners.
Recruitment and consent
Potential participants (identified via secondary or pri-
mary care or self-referred) will be sent a trial information
pack (Key Facts sheet, a set of Participant Information
Sheets, two screening measures (FSS & APDDS),
response slips (interested to hear more/decline to partici-
pate, plus reasons why) and a prepaid envelope. They will
be asked to return a reply slip and the two completed
screening measures in a prepaid envelope to the Local
Investigator (LI) if they wish to find out more about the
trial, or a decline slip, if they would prefer not to receive
any further information. Individuals who have not
responded will be sent a second trial information pack
two weeks later and a final invitation to participate one
month later.
The LI in each centre will telephone those who have
expressed an interest in the trial and give them an oppor-Thomas et al. BMC Neurology 2010, 10:43
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tunity to ask questions. If, after this discussion, the indi-
vidual still wishes to take part, the LI will undertake a
screening using a checklist. After screening, participants
will be notified via the telephone whether they are eligible
or ineligible. Participants who are currently ineligible (e.g.
due to medication recently started, a planned holiday,
having received fatigue advice etc.) but who may fulfil eli-
g i b i l i t y  c r i t e r i a  a t  a  l a t e r  d a t e  w i l l  b e  h e l d  o v e r  t o  b e
rescreened (if another iteration is scheduled in the cen-
tre). Individuals who are ineligible will be sent a letter
notifying them of this, along with a booklet produced by
the MS Society about MS-fatigue [54].
Randomisation
T o ensure good allocation concealment, random alloca-
tion will be e-mail-based and administered at Poole Hos-
pital by the statistician who will be blinded to the identity
of participants. Once a block of participants from a cen-
tre have provided informed consent they will be formally
entered onto the trial database and an anonymised list of
their identification numbers will be sent to the statistician
who will randomly allocate half to the FMP group and
half to the current local practice group. This method
implies stratification by centre.
Outcome Measures
The following demographic information will be collected
before the start of the trial: age, sex, educational attain-
ment, marital status, number of children, length of time
since diagnosis, disease course, relapse history, employ-
ment status, prescribed drugs currently taken, co-morbid
medical conditions, disability level.
For those randomised to the FMP, outcomes will be
measured 1 week prior to the start of the programme and
1 month, 4 months and 12 months after the end of the
programme. For those randomised to current local prac-
tice, outcomes will be sent on the same dates as those
randomised to the FMP.
Primary Outcome Measures
These are all self-reported questionnaire measures and
specified a priori.
There are three primary outcomes:
1. Self-reported fatigue severity
The Fatigue Assessment Instrument (FAI) [55] is an
expanded version of the uni-dimensional Fatigue Severity
Scale (FSS) [51]. The FSS is one of the best known and
most used fatigue scales. It principally measures the
impact of fatigue on specific types of functioning. The
FAI has four subscales: fatigue severity, situation specific-
ity, consequences of fatigue, and responsiveness to rest/
sleep. Responses are made on a 7-point Likert-type scale.
The fatigue severity subscale of the FAI corresponds
almost exactly to the Fatigue Severity Scale, sharing eight
of the original nine items along with three additional
items. Scores on this subscale are a primary outcome.
The other subscales are secondary outcomes.
2. Self-reported MS-specific quality of life
The Multiple Sclerosis Impact Scale (MSIS-29) [56,57]
measures the physical (20 items) and psychological
impact (9 items) of MS on day-to-day life. It uses 5-point
Likert-type scales ranging from 'not at all' to 'extremely'
and is based on quality of life in the last two weeks. The
total score for the MSIS-29 is a primary outcome mea-
sure. The physical and psychological subscales will be
secondary outcomes.
3. Self-reported self-efficacy for managing fatigue
The Multiple Sclerosis-Fatigue Self-Efficacy (MS-FSE)
scale is adapted from the Control subscale of the MS Self-
Efficacy (MSSE) Scale developed by Schwartz [58]. This
adapted scale has undergone a preliminary validation in
our pilot research.
Secondary Outcome Measures
Self-reported fatigue
Three of the subscales from the FAI [55] (namely, situa-
tion specificity, consequences of fatigue and responsive-
ness to rest/sleep) along with the total score of the FAI.
Self-reported MS-specific quality of life
The subscale scores of the MSIS-29 [56,57] for the physi-
cal and psychological impact of MS.
Self-reported general quality of life
1. The Medical Outcomes Short-Form Survey version 2
(SF-36v2) [59,60] measures eight dimensions: physical
functioning, role limitations because of physical health
problems, bodily pain, general health perceptions, vital-
ity, social functioning, role limitations because of emo-
tional problems, and mental health. It generates scores
for the eight dimensions as well as two summary mea-
sures (physical health and mental health). It uses Likert-
type response scales. This measure will also be used to
calculate Quality Adjusted Life Years (QALYs) for the
economic analysis.
2. The EuroQoL (EQ-5D) [61] is a standardised instru-
ment for use as a measure of health outcome. It has been
developed by the EuroQoL Group as a simple, generic
measure of health status, and is applicable to a wide range
of health conditions. The EQ-5D consists of the EQ-5D
descriptive system and the EQ visual analogue scale (EQ
VAS) and it allows the derivation of a single index value
for health status. The EQ-5D descriptive system com-
prises five dimensions (mobility, self-care, usual activi-
ties, pain/discomfort and anxiety/depression) each rated
on three levels (no problems, some problems, severe
problems). The EQ VAS records the respondent's self-
rated health on a vertical, visual analogue scale where the
endpoints are labelled 'best imaginable health state' and
'worst imaginable health state'.Thomas et al. BMC Neurology 2010, 10:43
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Self-reported mood
The Hospital Anxiety and Depression Scale (HADS) [62]
is a self-report measure consisting of an anxiety and a
depression subscale. Each subscale consists of 7 items
with a 4-point Likert-type response scale.
Self-reported fatigue severity
The Fatigue Symptom Inventory (FSI) [63,64] is a 14-item
self-administered multi-dimensional questionnaire which
measures the severity, frequency, and diurnal variation of
fatigue and its perceived interference on quality of life.
Severity is measured using four separate items that assess
most, least, and average fatigue in the past week, as well
as current fatigue. Frequency is measured using two sepa-
rate items that assess the number of days in the past week
that respondents felt fatigued, as well as the portion of
the day on average they felt fatigued. Diurnal variation is
measured using a single item that provides descriptive
information about daily patterns of fatigue. Perceived
interference is measured using seven separate items.
Self-reported sleep quality
These questions have been modified from the MS Clini-
cal Practice Guidelines sleep questionnaire [7]. Questions
include duration and quality of night-time sleep, factors
that may prevent or interrupt sleep, and daytime sleeping
and sleepiness.
Self-reported resource utilisation
A resource utilisation questionnaire will be administered
at 4- and 12-month follow-up. It is adapted from one util-
ised in a large randomised controlled trial in Parkinson's
disease [65], and includes questions about health and
social service contacts in the preceding 3 months.
Self-reported fatigue management strategies
To gain deeper insights into the results of the trial, at the
4-month follow-up we will administer a semi-structured
questionnaire to participants randomised to the FMP. In
the questionnaire (which draws upon an existing ques-
tionnaire [66]) they will be asked to describe whether
they have tried to make any changes to their lifestyle,
behaviour, or thinking, as a result of the intervention;
whether these changes have been made successfully or
unsuccessfully, and the reasons why. The information
they provide will be analysed both quantitatively (for
example, number of lifestyle changes, number of suc-
cesses) and qualitatively (identifying emergent themes in
the responses given [67,68]). In this way, we will be able to
look closely at "adherence" to the key principles of the
intervention, which will help in the interpretation of the
trial results.
Objective measure of physical activity
The  activ  PAL™ accelerometer classifies an individual's
free-living activity into periods spent lying/sitting, stand-
ing and walking [69]. This information can be used to
estimate daily energy expenditure, and time spent resting.
Data will be collected at baseline and at 1- and 4-month
follow-up. A postal method of administration was tested
during an earlier research phase.
Self-reported satisfaction
Participants in the intervention arm will be asked to com-
plete a brief semi-structured evaluation questionnaire at
the end of each session of the fatigue management pro-
gramme. This questionnaire was used in the pilot phases
of the research [45].
Intervention
The group-based fatigue management intervention [45]
is based upon a conceptual framework that integrates ele-
ments from cognitive behavioural [70], social-cognitive
[71], energy effectiveness, self-management [72] and self-
efficacy [73] theories.
The intervention focuses on the management of
fatigue, the most common symptom of MS, and is likely
to be relevant to many people. However , it is expected
that it will also provide a framework to help people man-
age their MS more generally. A cognitive behavioural
approach that focuses on one symptom is likely to be
clearer and less overwhelming than one encompassing
many aspects, can be achieved in a smaller number of
sessions, and will be easier to integrate within existing
services.
The intervention consists of six sessions held on a
weekly basis; the first, 2 hours' duration, and subsequent
sessions, 1.75 hours' duration (each with a 15 minute
refreshment break halfway through). It is designed to be
run by two health professionals with experience of work-
i n g  w i t h  p e o p l e  w i t h  M S  a n d  o f  g r o u p - w o r k  ( s u c h  a s
occupational therapists, nurses, or physiotherapists).
This latter feature enables the intervention to be incorpo-
rated into existing health service structures. The inter-
vention will be delivered to groups of 6-12 people.
Participants are encouraged to bring along a "support-
ive other" to the first session. Since the intervention
entails participants making lifestyle changes, the involve-
ment of a "supportive other" could help to encourage and
support them in making such changes. Contact between
members of the group outside the formal group setting
will be encouraged, as an additional source of support.
The intervention is manualised and sessions are deliv-
ered via PowerPoint. A summary of programme content
is presented in Table 1. The facilitator manual (~100
pages) provides detailed session information, guidance
on preparation and delivery, a checklist of facilitator
objectives and signposts to additional resources. There is
also a companion participant workbook to reinforce
material from the programme. Facilitators will be trained
at one day orientation workshops and psychological
advice and debriefing will be available for facilitators
throughout the trial.Thomas et al. BMC Neurology 2010, 10:43
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The aim of the intervention is to help people manage
their fatigue by:
1. Normalising the experience of fatigue
2. Using their available energy more effectively
3. Developing "helpful thinking styles" about fatigue
Missed sessions
If participants do not attend a session they will be sent
the materials they missed and, where possible, the session
will be held over the telephone. Participants receiving the
intervention will continue to have access to services avail-
able as part of their usual local care.
Control group
Participants randomised to this arm of the trial will
receive current local practice. Inevitably, there will be
minor variations in the exact composition of what is usu-
ally provided, both within and between centres; depend-
ing on local resources and patient need. We consider this
minor variation in current local practice to be a strength
of the trial as it will increase the applicability of the find-
ings to a wider range of centres. Individuals who have
recently received substantive fatigue management are not
eligible for the trial (see exclusion criteria).
Results
Statistical analysis
We will conduct two sets of statistical analyses. The pri-
mary analysis will be an intention-to-treat analysis,
whereby participants are analysed in the arm of the trial
they were randomised to, regardless of how many ses-
sions of the programme they attend. In order for an
intention-to-treat analysis to be conducted, we will
endeavour to collect outcome measures for everyone
(while recognising the right of participants to withdraw
from the trial at any stage). The secondary analysis will be
conducted on a "per protocol" basis. This analysis will
exclude participants who attend fewer than four sessions
of the fatigue management programme.
Data will be analysed primarily using SPSS for Win-
dows. A 5% significance level will be used. Outcome mea-
sures will be assumed to be interval scaled, and the
analysis will initially be focused on absolute change in
outcome post-intervention relative to baseline, and abso-
lute change in outcome at 4- and 12-month follow-up,
relative to baseline. These change scores, presented sepa-
rately for the three follow-up periods, are being used
because we think they are the most clinically useful. They
are likely to be normally distributed (this assumption will
be checked). Change scores will be compared between
the two groups using the independent samples t-test.
Additional analyses will be conducted to address the
following issues:
1. We will adjust for baseline variability/baseline differ-
ences between treatment arms. For each outcome vari-
able analysed, these would include the baseline
measurement for that outcome, baseline primary out-
Table 1: Summary of content of the Fatigue Management Programme
Session Title Content Homework
1 What is MS-related fatigue? General introduction; expectations;
icebreaker (quiz); types of fatigue; contributory 
factors, conceptual
model of fatigue in MS
Activity/fatigue diary
2 Opening an "energy account" Rest - functions; barriers; relaxation types and 
techniques; diaphragmatic breathing exercise; sleep 
hygiene
Rest/activity/sleep planner
3B u d g e t i n g  e n e r g y  &  
smartening up goals
Types of activity; balancing activity & rest; 
moderating activity using the toolbox; goal-setting
Goal-setting exercise
4 The stress response; 
Introducing the cognitive 
behavioural model
The stress response (fight-or-flight); ways of coping 
with stress; introducing the cognitive behavioural 
model
'Unhelpful thoughts related 
to fatigue' diary
5 Putting unhelpful thoughts on 
trial
Unhelpful thought patterns related to fatigue; 
challenging unhelpful thoughts; levels of belief
Thought challenge sheet
6 Recapping & taking the 
programme forward
Revisiting expectations; group activity to revisit 
themes of the programme; rationale of 'Keeping on 
Track' planner
'Keeping on Track' plannerThomas et al. BMC Neurology 2010, 10:43
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come measures, gender, age, marital status, education
level, type of MS, time since diagnosis, and level of dis-
ability.
2 .  A l t h o u g h  p a r t i c i p a n t s  i n  t h e  t r i a l  h a v e  b e e n  r a n -
domised individually, for those randomised to the fatigue
management intervention, it is possible that the group-
based nature of the intervention will result in observa-
tions that are clustered. This could result in misleading
statistical tests [74]. We will assess the extent to which
this occurs by incorporating clustering into the analysis.
3. It is likely that outcome data will be missing for some
participants. In the main analysis such individuals will be
excluded. However, the implied assumption that the data
are "Missing Completely At Random" might not be cor-
rect, potentially leading to biased estimates of the effect
of the intervention [75]. Two methods will be used to
assess the extent to which this occurs: Firstly, we will use
the "Last Observation Carried Forward" imputation
method (which assumes no change in outcome when a
data point is missing). Secondly, we will use a mixed
model for repeated measurements.
4. Analysing the change in outcome from baseline to
each time point will, we believe, result in the most clini-
cally useful presenta tion of results. However , to gain a
deeper understanding of how outcome measures change
over the course of follow-up, we will also model all mea-
surement occasions together for each outcome.
5 .  I t  i s  p o s s i b l e  t h a t  t h e  f a t i g u e  m a n a g e m e n t  p r o -
gramme might be more effective in certain sub-groups of
individuals. We will examine these potential effect modi-
fiers by testing the relevant "treatment x effect modifier"
interaction terms. However, we acknowledge that these
statistical tests are likely to be underpowered, since this
was not a specific aim of the study. In these analyses, we
will consider study centre, baseline fatigue, gender, age,
marital status, type of MS, time since diagnosis, and level
of disability.
These additional analyses will involve the use of a vari-
ety of techniques including multi-level/mixed models. In
addition to these pre-specified analyses, we will also con-
duct further exploratory analyses as suggested by the
data.
Presentation of the results will follow the Consolidated
Standards of Reporting Trials (CONSORT) [76,77] guide-
lines, in such a way that they can be meaningfully incor-
porated into systematic reviews. The design of the trial
will help ensure that it is graded as high quality in system-
atic reviews.
Economics evaluation
The economic burden of MS on the health services, on
people with MS, their families (and/or carers) and society
is high [78]. We recognise this as an important issue, and
one that should be considered in the context of clinical
trials. This is especially relevant in the United Kingdom
NHS, where health policy decision makers (e.g. National
Institute for Health and Clinical Excellence (NICE)) are
interested in both the clinical value and cost-effectiveness
of interventions. Therefore, alongside the proposed clini-
cal trial, an economic evaluation will be undertaken to
assess the incremental costs, incremental benefits, and
the resulting cost-effectiveness of introducing a group-
based cognitive behavioural approach to managing
fatigue in people with MS, compared with current local
practice (excluding the intervention).
It is anticipated that the primary economic endpoint
will involve a clinically significant improvement in fatigue
(e.g. cost per unit change in the fatigue outcome mea-
sure). Thereafter, the economic evaluation will estimate
the cost per unit change in quality of life (e.g. MSIS-29,
SF-36), and it will estimate the cost per Quality Adjusted
Life Year (QALY) associated with the introduction of the
group-based cognitive behavioural approach, as a more
meaningful and policy relevant outcome. QALY esti-
mates will be based on individual patient level data col-
lected in the trial using the SF-36 and the EQ-5D. The
economic assessment will explore the longer term conse-
quences of improvements identified (expected) in fatigue
and quality of life, modelling outcomes over time, where
possible and appropriate, on the basis of the findings
from the proposed trial. Where modelling of costs and
consequences is undertaken, it will follow guidelines for
good practice reported by Phillips and colleagues [79].
Perspective
A broad perspective to the measurement of costs and
outcomes will be adopted, and results will be presented
separately from the perspective of the NHS and personal
social services (i.e. Third Party Payer), and from a broader
societal perspective.
Data Collection
Trial data will be used to consider the relative effective-
ness of the intervention versus comparator, and primary
and secondary outcome measures have been described
above. Patient level data will be collected within the trial
both pre- and post-intervention, and at 4- and 12-month
follow-up for those in the fatigue management arm of the
trial and equivalent time points post-randomisation for
those receiving current local practice. The primary eco-
nomic analysis of outcomes will be between baseline and
4-month follow-up, although analysis using the shorter
time horizon, and other longer term modelled outcomes
will also be presented.
Resource use data will be collected over the 4-month
follow-up period and will primarily comprise the direct
delivery of the group-based cognitive behavioural
approach (e.g. staff time, related consumables, and any
travel costs for the health professional). Record forms will
be used by staff delivering the intervention to identifyThomas et al. BMC Neurology 2010, 10:43
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staff time used, and the main categories of staff time (e.g.
delivery of sessions, preparation, setting-up) and semi-
structured interviews will be held with each of the Service
Providers (centres) to estimate the broader resource use
associated with delivery of the intervention.
Further data on NHS and personal social services
resource use (e.g. related hospitalisation, Accident and
Emergency Department visits, and General Practitioner
visits) and information on carer time will be gathered
using a simple patient self-completion questionnaire
(completed at 4- and 12- month follow-up), and differ-
ences between groups will be investigated and reported
as part of the economic analysis.
Cost Analysis
Cost analysis will estimate direct costs (i.e. those costs
directly associated with the delivery of the intervention
and the related follow-up of patients), using resource use
data collected within the RCT, and staff and unit cost
data from credible sources (national statistics and data
from participating centres e.g. salary scales). Other costs
will be determined using the data from the patient ques-
tionnaire and appropriate sources for unit cost data (e.g.
Personal Social Services Research Unit (PSSRU), Univer-
sity of Kent at Canterbury , NHS Reference costs, local
NHS Trust cost data). A mean net cost per patient in each
arm of the trial and an incremental cost per patient, with
associated measures of variance, will be calculated. Statis-
tical analysis will characterise any uncertainty, and sub-
group analysis (e.g. by disease severity) will be presented.
All sources of cost data will be specified and all estimates
will be transparent. Sensitivity analyses will be under-
taken to address uncertainty within the unit cost esti-
mates.
Where costs and benefits are considered beyond a 12-
month time period, the evaluation will follow the present
National Health Service (NHS)/Department of Health
convention and discount future costs and future benefits
at 3.5% per year. Analysis will also report non-discounted
findings and findings where costs and benefits are subject
to a range of discounted rates.
Sensitivity Analyses
Uncertainty in data estimates/assumptions will be subject
to detailed sensitivity analysis, using plausible data
ranges, where results indicate this to be appropriate (e.g.
variations in staff grades and staff costs, variations in the
estimates for NHS resource use and the relevant unit
costs). Where data point estimates are not subject to sen-
sitivity analysis, reasons for this will be given. Where
undertaken, and as appropriate, sensitivity analysis will
comprise one-way analysis, multi-way analysis, scenario
analysis, and where modelling is undertaken, it will
include probabilistic sensitivity analysis.
Serious adverse events
Adverse events will be defined according to standard
clinical trial definitions and serious adverse events will be
reported to the Multi-centre Research Ethics Committee
(MREC) within 15 days by the Chief Investigator.
Data management
The trial data will be entered onto an SPSS spreadsheet
by an administrator . A random 10% sample of the data
will be checked for accuracy.
Participant withdrawal of consent to research follow-up
If a participant withdraws consent to be included in
research follow-up during the trial, the local investigator
(LI) will be informed and will contact the participant.
Provided the participant is willing to give a reason, the LI
will find out why (s)he wishes to withdraw from the
research follow-up. The LI will also determine whether
the participant has given permission to retain data col-
lected before withdrawal for use at final analysis, or
whether this information should be destroyed. No data
will be used in the analysis without a participant's con-
sent.
Discussion
This is a pragmatic trial aimed at answering the question
of whether introducing the intervention into a service has
a significant impact on fatigue, self-efficacy, and quality
of life, and whether it represents value for money to the
NHS. These are the most important questions from a
health service and patient perspective.
A strength of this trial is the fact that the mixed meth-
odology pilot work (intervention development and pro-
cess and preliminary evaluation) underpinning the trial
has been rigorously conducted and documented follow-
ing the Medical Research Council guidance for the devel-
opment of a complex intervention [46]. The intervention
is fully manualised and supported by training and Power-
Point materials meaning that it can be easily replicated in
a standardised form. The multi-centre nature of the trial
gives the opportunity to test whether the intervention
transfers successfully to other geographic areas. The
intervention has been developed so that it can be deliv-
ered by those already routinely involved in the care of
people with MS. Thus, if found to be beneficial, it could
be readily incorporated into existing services, facilitating
the integration of psychology-based approaches into
patient care. The 12-month follow-up period offers the
opportunity to explore and assess longer term effects.
Service users have been involved throughout the
research process, from the pilot work through to the RCT
(as lay grant application and document reviewers, focus
group participants, trial participants and as members of
the steering group). Participants randomised to the inter-
vention arm will have an opportunity to provide satisfac-
tion and process feedback via session evaluation
questionnaires and a semi-structured questionnaire
administered at the second follow-up.Thomas et al. BMC Neurology 2010, 10:43
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